Claire Armstrong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Claire Armstrong has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Sabrina Leigh Spencer
Department of Biochemistry, University of Colorado, Boulder, USA
4 shared publications - Victor J. Passanisi
Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA
2 shared publications Chen Yang
Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA
1 shared publication- Christopher R. Ill
Department of Biochemistry and BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA
1 shared publication Humza M. Ashraf
Department of Biochemistry, University of Colorado Boulder, Boulder, CO 80303, USA; BioFrontiers Institute, University of Colorado Boulder, Boulder, CO 80303, USA
1 shared publication- Humza M. Ashraf
Department of Biochemistry, University of Colorado
1 shared publication
Latest Publications
- 1 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 16 (796) , eade8744
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of adaptation and resume slow proliferation. Here, we found that this phenomenon is common to many cancer types driven by EGFR, KRAS, or BRAF mutations in response to multiple, clinically approved MAPK pathway inhibitors. In 2D cultures and 3D spheroid models of various cancer cell lines, a subset of cells escaped drug-induced quiescence within 4 days to resume proliferation. These “escapee” cells exhibited DNA replication deficits, accumulated DNA lesions, and mounted a stress response that depended on the ataxia telangiectasia and RAD3-related (ATR) kinase. We further identified that components of the Fanconi anemia (FA) DNA repair pathway are recruited to sites of mitotic DNA synthesis (MiDAS) in escapee cells, enabling successful completion of cell division. Analysis of patient tumor samples and clinical data correlated disease progression with an increase in DNA replication stress response factors. Our findings suggest that many MAPK pathway–mutant cancers rapidly escape drug action and that suppressing early stress tolerance pathways may achieve more durable clinical responses to MAPK pathway inhibitors.
- 1 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 16 (796) , eade8744
Multiple cancers escape from multiple MAPK pathway inhibitors and use DNA replication stress signaling to tolerate aberrant cell cycles
Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of adaptation and resume slow proliferation. Here, we found that this phenomenon is common to many cancer types driven by EGFR, KRAS, or BRAF mutations in response to multiple, clinically approved MAPK pathway inhibitors. In 2D cultures and 3D spheroid models of various cancer cell lines, a subset of cells escaped drug-induced quiescence within 4 days to resume proliferation. These “escapee” cells exhibited DNA replication deficits, accumulated DNA lesions, and mounted a stress response that depended on the ataxia telangiectasia and RAD3-related (ATR) kinase. We further identified that components of the Fanconi anemia (FA) DNA repair pathway are recruited to sites of mitotic DNA synthesis (MiDAS) in escapee cells, enabling successful completion of cell division. Analysis of patient tumor samples and clinical data correlated disease progression with an increase in DNA replication stress response factors. Our findings suggest that many MAPK pathway–mutant cancers rapidly escape drug action and that suppressing early stress tolerance pathways may achieve more durable clinical responses to MAPK pathway inhibitors.
- Open Access
- 9 July 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112768
Cyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis
- 9 July 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (7) , 112768
Open AccessCyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis
- Open Access
Cyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis
Summary: Faithful DNA replication requires that cells fine-tune their histone pool in coordination with cell-cycle progression. Replication-dependent histone biosynthesis is initiated at a low level upon cell-cycle commitment, followed by a burst at the G1/S transition, but it remains unclear how exactly the cell regulates this change in histone biosynthesis as DNA replication begins. Here, we use single-cell timelapse imaging to elucidate the mechanisms by which cells modulate histone production during different phases of the cell cycle. We find that CDK2-mediated phosphorylation of NPAT at the Restriction Point triggers histone transcription, which results in a burst of histone mRNA precisely at the G1/S phase boundary. Excess soluble histone protein further modulates histone abundance by promoting the degradation of histone mRNA for the duration of S phase. Thus, cells regulate their histone production in strict coordination with cell-cycle progression by two distinct mechanisms acting in concert.
Open AccessCyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis
Summary: Faithful DNA replication requires that cells fine-tune their histone pool in coordination with cell-cycle progression. Replication-dependent histone biosynthesis is initiated at a low level upon cell-cycle commitment, followed by a burst at the G1/S transition, but it remains unclear how exactly the cell regulates this change in histone biosynthesis as DNA replication begins. Here, we use single-cell timelapse imaging to elucidate the mechanisms by which cells modulate histone production during different phases of the cell cycle. We find that CDK2-mediated phosphorylation of NPAT at the Restriction Point triggers histone transcription, which results in a burst of histone mRNA precisely at the G1/S phase boundary. Excess soluble histone protein further modulates histone abundance by promoting the degradation of histone mRNA for the duration of S phase. Thus, cells regulate their histone production in strict coordination with cell-cycle progression by two distinct mechanisms acting in concert.
- Open Access
- 29 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (31)
Replication-dependent histone biosynthesis is coupled to cell-cycle commitment
Significance: Current thinking limits replication-dependent (RD) histone biosynthesis to S phase of the cell cycle, with histone production initiated concomitantly with DNA replication. This work examines the cell-cycle timing of RD histone biosynthesis in single human cells and shows that while there is indeed a burst of RD histone production in S phase, RD histone production actually begins earlier in G1, at the point of cell-cycle commitment. These results demonstrate that cells born committed to the subsequent cell cycle build up a small pool of histones before initiating DNA replication, thereby safeguarding against a loss of genome integrity, and are distinct from cells that have exited the cell cycle and do not require histone synthesis until cell-cycle reentry.
- 29 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (31)
Open AccessReplication-dependent histone biosynthesis is coupled to cell-cycle commitment
Significance: Current thinking limits replication-dependent (RD) histone biosynthesis to S phase of the cell cycle, with histone production initiated concomitantly with DNA replication. This work examines the cell-cycle timing of RD histone biosynthesis in single human cells and shows that while there is indeed a burst of RD histone production in S phase, RD histone production actually begins earlier in G1, at the point of cell-cycle commitment. These results demonstrate that cells born committed to the subsequent cell cycle build up a small pool of histones before initiating DNA replication, thereby safeguarding against a loss of genome integrity, and are distinct from cells that have exited the cell cycle and do not require histone synthesis until cell-cycle reentry.